Merck & Co., Inc. (MRK) News Today

Merck & Co., Inc. (NYSE: MRK) shares have decreased in the latest session despite trading near their 52-week high. Recent coverage highlights strong growth from Keytruda, optimism about Merck’s pipeline, and a more favorable analyst outlook, but investors remain focused on valuation, the 2028 Keytruda patent expiration, and lingering Gardasil weakness.

• Positive Sentiment: Guggenheim raised its price target to $170 from $146 and reiterated a “Buy” rating, implying roughly 14.5% upside from the referenced price. The upgrade provides a bullish signal and may support MRK by indicating confidence in Merck’s earnings outlook and product pipeline. Benzinga analyst note
• Positive Sentiment: Keytruda continues to drive Merck’s growth, while newer products and pipeline programs could help offset the expected impact of the drug’s 2028 patent cliff. The company’s strong recent return and revenue momentum reinforce the longer-term growth case. Merck trading near 52-week high analysis
• Neutral Sentiment: Merck will participate in Morgan Stanley’s 24th Annual Global Healthcare Conference. The event could provide updates on Keytruda, Gardasil, pipeline assets, and post-2028 planning, but no new financial information was disclosed in the announcement. Morgan Stanley healthcare conference announcement
• Neutral Sentiment: Merck is participating in a cocoa traceability and digital product-passport pilot with The Hashgraph Group and PwC Germany. The initiative may support corporate sustainability efforts but is unlikely to materially affect near-term earnings. Cocoa traceability partnership
• Negative Sentiment: MRK’s valuation is elevated after its substantial rally, increasing the risk that investors will demand continued strong execution. Analysts and investors are also watching whether Merck can replace Keytruda revenue after the 2028 patent expiration. Merck Gardasil and future growth analysis
• Negative Sentiment: Gardasil’s earlier sales decline remains part of the investment debate, even though management is now emphasizing longer-term growth opportunities. Continued vaccine-market pressure could weigh on sentiment until the company demonstrates a sustained recovery. Gardasil outlook analysis